The global lung disease therapeutics market size accounted for USD 91.31 billion in 2024, grew to USD 96.82 billion in 2025, and is expected to be worth around USD 164.13 billion by 2034, registering a healthy CAGR of 6.04% between 2024 and 2034. The North America lung disease therapeutics market size is predicted to increase from USD 32.87 billion in 2024 and is estimated to grow at the fastest CAGR of 6.19% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lung Disease Therapeutics Market
5.1. COVID-19 Landscape: Lung Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lung Disease Therapeutics Market, By Disease Type
8.1. Lung Disease Therapeutics Market, by Disease Type, 2024-2034
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Lung Cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Chronic Obstructive Pulmonary Disease (COPD)
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Lung Disease Therapeutics Market, By Drug Class
9.1. Lung Disease Therapeutics Market, by Drug Class, 2024-2034
9.1.1. Corticosteroids
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Bronchodilator
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Antimicrobial
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Alkylating Agents
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Mucolytics
9.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Lung Disease Therapeutics Market, By Molecule Type
10.1. Lung Disease Therapeutics Market, by Molecule Type, 2024-2034
10.1.1. Small molecules
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Biologics
10.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Lung Disease Therapeutics Market, By Treatment Type
11.1. Lung Disease Therapeutics Market, by Treatment Type, 2024-2034
11.1.1. Chemotherapy
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Immunotherapy
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Targeted Therapy
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Radiation Therapy
11.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Lung Disease Therapeutics Market, By Distribution Channel
12.1. Lung Disease Therapeutics Market, by Distribution Channel, 2024-2034
12.1.1. Online
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Hospital
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Retail
12.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 13. Global Lung Disease Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.1.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.2.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.2.7. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.2.10. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.3.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.4.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.5.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Molecule Type (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
Chapter 14. Company Profiles
14.1. Johnson & Johnson
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AstraZeneca
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Boehringer Ingelheim
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Allergan Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bristol-Myers Squibb Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Eli Lilly and Company
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Hoffmann-La Roche
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample